Study of GS-4528 in Adults With Solid Tumors (NCT05840224)
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-4528 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe to give to people alone or in combination with Anti-PD-1 Monoclonal Antibody. The primary objectives of this study are: * To assess the safety and tolerability of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended Phase 2 dose (RP2D) of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: The University of Washington/FHCC — Seattle, Washington
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- The University of Washington/FHCC — Seattle, Washington
- The Ottawa Hospital — Ottawa,
- University Health Network, Princess Margaret Cancer Centre — Toronto,
- Asan Medical Center — Seoul,
- Severance Hospital, Yonsei University Health Systems — Seoul,
- Samsung Medical Center — Seoul,
- NEXT Oncology-Hospital Quironsalud Barcelona - Unidad de Ensayos Fase 1 — Barcelona,
- Hospital Universitari Vall D'Hebron- Oncology Service — Barcelona,
- START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I — Madrid,
- START MADRID_HM Sanchinarro-CIOCC-Unidad de Ensayos Fases I — Madrid,
- Clinica Universidad de Navarra- Unidad Central de Ensayos Clinicos — Pamplona,
- Taichung Veterans General Hospital — Taichung,
- National Taiwan University Hospital — Taipei,
- Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation — Taoyuan,
- St Bartholomew's Hospital — London,
- The Royal Marsden NHS Foundation Trust — Sutton,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.